Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Abstract Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAFV600E/K-mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune microenvironment; however, the links are poorly understood. We show that BRAFi + MEKi caused durable melanoma regression in an immune-mediated manner. BRAFi + MEKi treatment promoted cleavage of gasdermin E (GSDME) and release of HMGB1, markers of pyroptotic cell death. GSDME-deficient melanoma showed defective HMGB1 release, reduced tumor-associated T cell and activated dendritic cell infiltrates in response to BRAFi + MEKi, and more frequent tumor regrowth after drug removal. Importantly, BRAFi + MEKi–resistant disease lacked pyroptosis markers and showed decreased intratumoral T-cell infiltration but was sensitive to pyroptosis-inducing chemotherapy. These data implicate BRAFi + MEKi–induced pyroptosis in antitumor immune responses and highlight new therapeutic strategies for resistant melanoma. Significance: Targeted inhibitors and immune checkpoint agents have advanced the care of patients with melanoma; however, detailed knowledge of the intersection between these two research areas is lacking. We describe a molecular mechanism of targeted inhibitor regulation of an immune-stimulatory form of cell death and provide a proof-of-principle salvage therapy concept for inhibitor-resistant melanoma. See related commentary by Smalley, p. 176. This article is highlighted in the In This Issue feature, p. 161
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“induction of ICD (Box 1) (Erkes et al., 2020; Wang et al., 2020a)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Erkes et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Knight, D. A., Ngiow, S. F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N. M., Kinross, K., Yagita, H., Koya, R. C., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66236 · Cited by 269
RetractedGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680 · cited 3×
“We confirmed the ability of etoposide and also tested doxorubicin, a known chemotherapeutic inducer of pyroptosis, for ability to cause GSDME cleavage in CRT cell lines (31,32,34).”
BackgroundSelf-citationToll-like receptors: critical proteins linking innate and acquired immunity
Akira, S., Takeda, K., & Kaisho, T. (2001) · Nature Immunology · doi:10.1038/90609 · Cited by 4,777 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundRelease of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221 · cited 1×
“Released HMGB1 is known to promote inflammation through its binding to toll-like receptor 4 on dendritic cells (45, 46).”
BackgroundClassification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationInflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202 · cited 1×
“It has recently been shown that the intrinsic apoptotic pathway intersects with a distinct form of cell death termed pyroptosis that is gasderminmediated and involves pore-based release of immune stimulatory factors (28-31).”
BackgroundChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 1×
“This pore formation causes the release of immune stimulants, including HMGB1, which are able to induce dendritic cell (DC) activation and, in turn, propagate antitumor T-cell activity (32, 33, 35).”
Background
Cited by
Items 201–300 of 520
Zeng, Y., Cai, Y., Chai, P., Mao, Y., Chen, Y., Wang, L., Zeng, K., Zhan, Z., Xie, Y., Li, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961933 · Cited by 20
“On the other hand, a loss of pyroptosis was observed in BRAF inhibitor + MEK inhibitor-resistant tumors (66).”
BackgroundNinjurin 2 Modulates Tumorigenesis, Inflammation, and Metabolism via Pyroptosis
Zhang, J., Kong, X., Yang, H. J., Zhang, W., Chen, M., & Chen, X. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.01.013 · Cited by 20
“16,17 Interestingly, recent studies have shown that loss of NINJ1 inhibits plasma membrane rupture (PMR) and, thus, protects microphages from pyroptosis.”
Austin, E., Huang, A., Wang, J. Y., Cohen, M., Heilman, E. R., Maverakis, E., Michl, J., & Jagdeo, J. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.928484 · Cited by 20
Li, Z., Liu, Y., Lin, B., Yan, W., Yi, H., Wang, H., & Wei, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.925338 · Cited by 20
“There is increasing evidence that indicates cross-talk between pyroptosis and the TME mediates tumor development and progression (Runa et al., 2017; Orning et al., 2019; Erkes et al., 2020).”
BackgroundCASP6 predicts poor prognosis in glioma and correlates with tumor immune microenvironment
Guo, K., Zhao, J., Jin, Q., Yan, H., Shi, Y., & Zhao, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.818283 · Cited by 20
“PRGs regulate the TIME through various mechanisms (42, 43).”
BackgroundMolecular mechanisms and therapeutic relevance of gasdermin E in human diseases
Wang, J., Ye, T., Wang, S., Wang, J., & Jin, Y. H. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110189 · Cited by 19
Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma
Glasheen, M. Q., Caksa, S., Young, A. G., Wilski, N. A., Ott, C. A., Chervoneva, I., Flaherty, K. T., Herlyn, M., Xu, X., Aplin, A. E., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0025 · Cited by 19
Self-citationYang, X. Y., Cui, X., Wang, G., Zhou, M., Wu, Y., Du, Y., Li, X., & Xu, T. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23773 · Cited by 19
Hao, X., Tang, Y., Xu, W., Wang, M., Liu, J., Li, Y., He, J. H., Peng, Y., Sun, P., Liao, D., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03091-w · Cited by 19
“Pyropto-sis is a pro-inflammatory process that releases substantial amounts of immunostimulatory factors, such as high mobility group protein B1 (HMGB1), and induces immune activation [8, 9].”
Dying to survive: harnessing inflammatory cell death for better immunotherapy
Cheng, L., Wang, Y., & Zhang, Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.012 · Cited by 19
Qiu, B., Kline, C., & Mueller, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.674596 · Cited by 19
“Preclinical studies in melanoma have also revealed that combined BRAF and MEK inhibition induces cancer cell death via pyroptosis – a highly inflammatory form of programed cell death (66), which triggers an anti-tumor immune response that persists even after drug treatment is completed.”
BackgroundRoles of Pyroptosis-Related Gene Signature in Prediction of Endometrial Cancer Outcomes
Chen, Y., Liao, Y., Du, Q., Shang, C., Qin, S., Lee, K., Zou, Q., Liu, J., & Yao, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.822806 · Cited by 19
Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance
Sandri, S., Watanabe, L. R. M., de Oliveira, E. A., Faião‐Flores, F., Migliorini, S., Tiago, M., Felipe-Silva, A., Vazquez, V. D. L., Souza, P. D. C., Consolaro, M. E. L., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104998 · Cited by 19
Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition
Guardamagna, M., Berciano‐Guerrero, M., González, B. V., Pérez-Ruiz, E., Oliver, J., Lavado-Valenzuela, R., Rueda‐Domínguez, A., Barragán, I., & Queipo‐Ortuño, M. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911990 · Cited by 18
“agreed that BRAF inhibition also increases MHC expression and CD4+ and CD8+ T cell-response, but highlighted that MEK inhibition appears to act on T cell receptor (TCR)-mediated apoptosis [118].”
BackgroundLiang, X.-X., Liu, Q., Zhu, S., Li, Z., Chen, H., & Su, Z. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101796 · Cited by 18
“GSDM N-terminus is shared by all GSDMs except for DFNB59 [7], previous study demonstrated GSDME cleavage was required for HMGB1 release and induced pyroptosis [29].”
BackgroundRAF and MEK Inhibitors in Non-Small Cell Lung Cancer
Adamopoulos, C., Papavassiliou, K. A., Poulikakos, P. I., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094633 · Cited by 18
“This is supported by the absence of pyroptosis-related markers in BRAF and MEK-combined inhibition-resistant BRAF -mutant cancer models, which was associated with reduced T cell antitumor immunity and, importantly, was sensitive to pyroptosis-inducing chemotherapy [152].”
BackgroundManipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities
Miao, R., Wang, X., Zhang, J., Kang, Q., Liu, Q., Luo, X., Hou, J., & Gao, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00771-5 · Cited by 18
“Collectively, these findings highlight the potential of harnessing acute pyroptosis to stimulate antitumor immunity, with its targeted induction representing a promising strategy for improving cancer immunotherapy.”
InfluentialZhang, M.-J., Liang, M., Yang, S., Ma, X., Wan, S., Yang, Q., Wang, S., Xu, Z., & Sun, Z. (2023) · Chemical Communications · doi:10.1039/d2cc05498a · Cited by 18
Dong, X., Jin, C. G., Chen, D., Chen, Y., Ye, Z., Zhang, X., Huang, X., Zhang, W., & Gu, D.-N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.737867 · Cited by 18
“org 13 progression, and TME activity is closely associated with genomic instability (64, 65).”
BackgroundAhmed, F., Tseng, H., Ahn, A., Gunatilake, D., Alavi, S., Eccles, M. R., Rizos, H., Gallagher, S. J., Tiffen, J. C., Hersey, P., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.09.030 · Cited by 18
Tsai, Y., Chang, H.-Y., Hong, W.-Z., Chen, J.-Y., Chiang, S., Lin, Y. E., Ke, T.-W., Huang, C.-H., Chen, T.-H., Jiang, Y., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218132 · Cited by 17
Luo, M., Luan, X., Yang, C., Chen, X., Yuan, S., Cao, Y., Zhang, J., Xie, J., Luo, Q., Chen, L., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397863 · Cited by 18
“The caspase-3/GSDME axis acts as a switch between these two forms of cell death, signi fi cantly impacting conditions like lung cancer and melanoma (95, 96).”
BackgroundTriggering Pyroptosis in Cancer
Johnson, D. E., & Cui, Z. (2025) · Biomolecules · doi:10.3390/biom15030348 · Cited by 17
“…tumors that relapse after this combination therapy remain susceptible to etoposide-and doxorubicin-induced pyroptosis, highlighting the potential of pyroptosis induction as a therapeutic strategy not only for primary tumors but also for recurrent tumors resistant to targeted therapies [58].”
Methionine metabolite spermidine inhibits tumor pyroptosis by enhancing MYO6-mediated endocytosis
Wu, J., Ding, C., Zhang, C., Xu, Z., Deng, Z., Wei, H., He, T., Long, L., Tang, L., Ma, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57511-4 · Cited by 17
“Recognizing the ability of pyroptosis to facilitate the release of DAMPs, which in turn activate dendritic cells (DCs) and subsequently enhance T-cell immunity within the TME 5,37 , we further explored the role of combination therapies in regulating pyroptosis to modulate TME.”
Niu, Z., Xu, Y., Li, Y., Chen, Y., & Han, Y. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022031 · Cited by 17
“[14] reported that combined use of BRAFi and MEKi targeted therapies promoted cleavage of GSDME and induced pyroptosis in SKCM.”
BackgroundPyroptosis, Metabolism, and Oxidation in Tumorigenesis: Mechanisms and Therapeutic Implications
Cao, Q., Zhang, J., Sun, D.-Y., Fu, J., Wu, W., Chen, X., Li, D., & Wang, P. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0257 · Cited by 18
“In a previous study, Erkes et al. (2020) found that pyroptosis of melanoma cells induced by GSDME and caspase-3 promotes the release of HMGB1, and its release activates dendritic cells, which in turn causes the proliferation and maturation of T cells and promotes antitumor immune responses.”
Liang, L., Yan, B., Liu, Y., Jiang, S., He, H., Huang, J., Liu, W., & Xie, L. (2022) · Disease Markers · doi:10.1155/2022/4534080 · Cited by 17
“BRAFi + MEKi-resistant tumor lacks markers of pyroptosis and shows reduced T-cell infiltration within the tumor [15].”
BackgroundGallois, C., Ambrosini, M., Lonardi, S., Alouani, E. L., Guimbaud, R., Overman, M. J., Sinicrope, F. A., Mazard, T., Decraecker, M., Ros, J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115645 · Cited by 15
Zhao, K., Li, X., Shi, Y., Lü, Y., Qiu, P., Deng, Z., Yao, W., & Wang, J. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.899496 · Cited by 16
Jiang, A., Liu, W., Liu, Y., Hu, J., Zhu, B., Fang, Y., Zhao, X., Qu, L., Lü, J., Liu, B., et al. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.06.003 · Cited by 16
“51 However, programmed death can also have pro-cancer effects in certain cancers, and Demuynck et al. found that ferroptosis in breast cancer cells increased oxidized lipid levels in the microenvironment, leading to reduced phagocytosis and antigen cross-presentation by dendritic cells, which helped…”
Two Worlds Collide: Unraveling the Role of the Immune System in BRAF–MEK Inhibitor Responses
Smalley, K. S. M. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1441 · Cited by 16
Xu, L., Hu, Y., & Liu, W. (2022) · Journal of Inflammation Research · doi:10.2147/jir.s349186 · Cited by 16
“Loss of GSDME gene will show defective HMGB1 release and decreased infiltration of T cells.(24) However, due to technical limitations, current studies only focused on one or two PRRs and immune cells.”
BackgroundCai, Y., Li, K., Lin, J., Liang, X., Xu, W., Zhan, Z., Xue, S., Zeng, Y., Chai, P., Mao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910490 · Cited by 16
Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma
Eroglu, Z., Chen, Y. A., Smalley, I., Li, J., Markowitz, J., Brohl, A. S., Tetteh, L. F., Taylor, H., Sondak, V. K., Khushalani, N. I., et al. (2023) · Cancer · doi:10.1002/cncr.35029 · Cited by 16
“24,25 In a second series of matched samples, the on ‐ treatment biopsy exhibited more dramatic changes characterized by a near total eradication of melanoma cells.”
BackgroundCisplatin induces acute liver injury by triggering caspase-3/GSDME-mediated cell pyroptosis
Wu, P.-P., Shen, X., & Zheng, S. (2024) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2024.09.010 · Cited by 15
Genomic, Immunological, and Clinical Characterization of Pyroptosis in Ovarian Cancer
Zhou, M., Li, B., Liu, J., & Li, H. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s344554 · Cited by 15
“Although progress has been made in the treatment of OV, most patients relapse after first-line treatment, depending on the tumor and non-tumor heterogeneity of the tumor and surrounding TME.”
BackgroundInfluentialZhou, X., Yao, L., Zhou, X., Cong, R., Luan, J., Wei, X., Zhang, X., & Song, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837155 · Cited by 15
“g 2 inducing tumor cell pyroptosis (19).”
MTUS1 is a promising diagnostic and prognostic biomarker for colorectal cancer
Cheng, L.-Y., Huang, M.-S., Zhong, H., Ru, H., Mo, S., Wei, C., Su, Z., Mo, X., Yan, L.-H., & Tang, W. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02702-2 · Cited by 15
“Furthermore, the repression of the MEK/ERK pathway can change the immune cell composition of the tumour immune microenvironment [45].”
BackgroundEpigenetic and transcriptional control of gasdermins
Cadena, C., Kornfeld, O. S., Lee, B. L., & Kayagaki, N. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101841 · Cited by 15
Li, Y., Lv, J., Shi, W., Feng, J. C., Liu, M., Gan, S., Wu, H., Fan, W., & Shi, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710110 · Cited by 15
“BRAFi + MEKi Caspase 3 — — (9) chemotherapy drugs or TNFa Caspase-3 — GSDME tumor/”
BackgroundXu, H., Lu, M., Liu, Y., Ren, F., & Zhu, L. (2023) · Journal of Cancer · doi:10.7150/jca.88485 · Cited by 14
“However, in recent years, many researchers have found that this special programmed cell death can occur not only in immune cells, but can also be induced in a variety of cancer cells under the action of many chemotherapy drugs or molecules in a GSDMD [7] or GSDME [8-12], GSDMC [13] and GSDMB [14, 15] mediated manner.”
BackgroundInfluentialInsight into the structure, function and the tumor suppression effect of gasdermin E
Long, Y., Jia, X., & Chu, L. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116348 · Cited by 14
The Role and Therapeutic Potential of Pyroptosis in Colorectal Cancer: A Review
Fang, Q. Z., Xu, Y., Tan, X., Wu, X., Li, S., Yuan, J., Chen, X., Huang, Q., Fu, K., & Xiao, S. (2024) · Biomolecules · doi:10.3390/biom14070874 · Cited by 14
“In addition, ICIs and pyroptosis were also found to show synergistic anti-tumor activity [117,128].”
BackgroundBiscop, E., Baroen, J., Backer, J. D., Berghe, W. V., Smits, E., Bogaerts, A., & Lin, A. G. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02178-x · Cited by 14
“These fi ndings hold great promise for advancing the fi eld of plasma oncology.”
BackgroundHu, Y., Yu, Q., Li, X., Wang, J., Guo, L., Huang, L., & Gao, W. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403493 · Cited by 14
Melanoma: Pathogenesis and Targeted Therapy
Fu, Y., Liu, J., Mo, Z., Wang, B., Deng, Y., & Jiang, Y. (2026) · MedComm · doi:10.1002/mco2.70566 · Cited by 15
“Third, patients previously received MEK inhibitors also influence the efficacy of PD-1 inhibitors [ 406, 421 ].”
Xu, L., Zheng, Q., & Liu, W. (2022) · BMC Cancer · doi:10.1186/s12885-022-09301-0 · Cited by 14
Qiu, P., Guo, Q., Pan, K., Chen, J., & Lin, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.890242 · Cited by 14
Pyroptosis Predicts Immunotherapy Outcomes Across Multiple Cancer Types
Li, S., Chen, P., Cheng, B., Liu, Y., Zhang, X., Xu, Q., Huang, M., Dai, X., Huang, K., Zhang, L., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109163 · Cited by 14
Pyroptosis: a new therapeutic strategy in cancer
Tuncer, M., & Alcan, S. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08482-6 · Cited by 14
“For melanoma treatment BRAFi+MEKi, BRAF inhibitors, and MEK inhibitors combination which are approved by FDA, has recently been discovered to show its tumor size reduction effects by induction of pyroptosis caspase-3/GSDME pathway [70].”
BackgroundSun, Y., Chu, S., Wang, R., Xia, R., Sun, M. J., Gao, Z., Xia, Z., Zhang, Y., Dong, S., & Wang, T. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128558 · Cited by 14
Targeting pyroptosis reverses KIAA1199-mediated immunotherapy resistance in colorectal cancer
Li, L., Zhao, L., Zhou, D., Yu, Y., Zhang, P., Zheng, J., Lin, Z., Yu, D., Ren, J., Zhang, J., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010000 · Cited by 13
Zhao, W., Li, L. Y., Ye, F. C., & Zhao, J.-W. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71138 · Cited by 14
“In malignant melanoma, combined BRAF/MEK inhibition induces caspase-3 activation and GSDME cleavage, with STAT3 potentially enhancing therapeutic effects by regulating inflammasome activation and pyroptosis-related gene expression [72].”
Zhou, Z., Wei, J., Lu, B. F., Jiang, W., Bao, Y., Luo, L., & Wang, W. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.763807 · Cited by 13
“For its immune defense function, pyroptosis is recognized as a general innate immune effector mechanism and involved in the regulation of tumor-immune microenvironment (TIME) (Jorgensen and Miao, 2015; Erkes et al., 2020).”
BackgroundDong, L., Vargas, C. P. D., Tian, X., Chu, X., Yin, C., Wong, A., & Yang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210376 · Cited by 13
“In ferroptosis and necroptosis, JUN and p38 MARK are activated, while in pyroptosis, p38 MAPK and extracellular signal-regulated kinase (ERK 1/2) are activated [22], mediating the production of transcription factors and pro-inflammatory cytokines.”
BackgroundInfluentialThe analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma
Han, J., Hu, Y., Ding, S., Liu, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974916 · Cited by 13
“According to various studies, the immune cells and stromal cells in the TME play critical regulatory roles in the OS patients’ prognosis (23, 24).”
BackgroundInfluentialZhang, Z., Zhang, X., Zhao, S., Feng, W., Huang, H., Ding, L., Chen, Y., & Chen, B. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140175 · Cited by 13
Zhu, Y.-R., Yang, Y., Ruan, D.-D., Que, Y.-M., Gao, H., Yang, Y.-Z., & Zhao, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041493 · Cited by 12
“In addition, the release of HMGB1 is related to cell membrane rupture, and the release of cell contents during pyroptosis further promotes the excretion of HMGB1, exacerbating local inflammation [44].”
The conflicting role highlights the complexity of GSDMs in cancer
He, S., Huang, Q., & Cheng, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1531695 · Cited by 12
Distinct Types of Regulated Cell Death in Melanoma
Wu, Q., Liang, S. A., Shi, G.-J., Meng, G., & Yang, S. (2025) · Cells · doi:10.3390/cells14110823 · Cited by 12
“The antitumor effectiveness of this combination facilitates the activation of Caspase-3 and GSDME, thereby inducing pyroptosis [75].”
Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives
Yang, Q., Sun, H., & Sun, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117043 · Cited by 12
Therapy‐Induced ECM Remodeling Creates a Transient Immune Barrier in Residual Melanoma
Hsu, C., Chen, J., Lee, K., Donahue, L. R., Kacaj, D., McDonough, S. P., & White, A. C. (2025) · Advanced Science · doi:10.1002/advs.202508451 · Cited by 12
Wang, Q., Liu, Q., Qi, S., Zhang, J., Liu, X., Li, X., & Li, C. (2022) · Cancers · doi:10.3390/cancers14010237 · Cited by 12
Li, Z., Yang, W., Liu, D., Ye, W., Du, G., & Li, X. (2022) · Scientific Reports · doi:10.1038/s41598-022-15854-8 · Cited by 12
Yang, J., Wang, C., Zhang, Y., Cheng, S., Xu, Y., & Wang, Y. (2023) · Journal of Ovarian Research · doi:10.1186/s13048-023-01275-2 · Cited by 12
“Most researches focused on only one or two pyroptosis-related genes (PRGs) and several cell types in the microenvironment, however, the tumor progression process is characterized by numerous genes and cell types interacting in a high-coordinated manner, which haven’t been fully understood yet [15, 16].”
BackgroundChen, C., Cheng, Y., Lei, H., Feng, X., Zhang, H., Qi, L., Wan, J., Xu, H., Zhao, X. Y., Zhang, Y., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115797 · Cited by 12
Xu, Z., Zhao, Y., Zhang, Y., Liu, X., Song, L., Chen, M., Xiao, G., Ma, X., & Shi, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1387647 · Cited by 12
Metabolic Inhibition Induces Pyroptosis in Uveal Melanoma
Varney, S. D., Erkes, D. A., Mersky, G. L., Mustafa, M. U., Chua, V. Y. L., Chervoneva, I., Purwin, T. J., Alnemri, E. S., & Aplin, A. E. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0508 · Cited by 12
Self-citationA novel identified pyroptosis-related prognostic signature of colorectal cancer
Chen, Z., & Tan, Z. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021433 · Cited by 12
“revealed that BRAFi and MEKi treatment promoted cleavage of gasdermin E (GSDME), a marker of pyroptosis, and induced tumor-associated T cell and activated dendritic cell infiltration [9].”
BackgroundCross-talk of pyroptosis and tumor immune landscape in lung adenocarcinoma
Wang, X., Lin, W., Liu, T., Xu, Z., Wang, Z., Cao, Z., Feng, X., Gao, Y., & He, J. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-715 · Cited by 12
“21037/tlcr-21-715 and regulate pyroptotic pathways and inhibit tumor growth including the doxorubicin, cisplatin, topotecan, etoposide and BRAF inhibitors/MEK inhibitors (29), which could reverse immunosuppressive microenvironment and reestablish local or systemic anti-tumor immunity (64).”
BackgroundGao, Y., Zhang, X., Li, Y., Gao, J., Liu, S., Cai, H., & Zhang, J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05074-6 · Cited by 12
Zhu, H., She, Q., Li, H., Zhang, N., Huang, W., Xu, Y., Liu, Z., & Liang, Y. (2024) · Toxicology · doi:10.1016/j.tox.2024.154018 · Cited by 12
Cell Death Modalities in Therapy of Melanoma
Wang, M., Zhao, J., Tang, M.-X., Li, M., Zhao, H., Li, Z., & Liu, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083475 · Cited by 11
“…(T22 peptide) [138] Activation of caspase 3 Raptinal [139] T-cell accumulation/activation, GSDM E cleavage, and release of HMGB1 PLX4720/PD0325901 [142] Activation of caspase 3 and GSDM E/D cleavage Temozolomide/chloroquine [140] Activation of gasdermin Phe-BF3 [143] Ferroptosis GPX4 inhibition…”
Mitochondrial pyruvate dehydrogenase phosphatase metabolism disorder in malignant tumors
Wang, Y., DANG, H., Wang, Q., Wu, S. W. N., Han, L., Luo, X., TIAN, Y., & Tang, H. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.063716 · Cited by 11
Gasdermins: multifunctional effectors of membrane permeabilization across cellular compartments
Margheritis, E. G., Gehle, N., & Cosentino, K. (2025) · FEBS Journal · doi:10.1111/febs.70215 · Cited by 11
“Moreover, increasing evidence supports their role in potentiating anti-tumor immunity through the promotion of immunogenic cell death [28 – 30].”
Overcoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis
Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 11
He, D., Liao, S., Xiao, L., Cai, L., You, M., He, L., & Huang, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739011 · Cited by 11
Chen, X., Yang, M., Wang, L., Wang, Y., Tu, J., Zhou, X., & Yuan, X. (2023) · BMC Cancer · doi:10.1186/s12885-023-10850-1 · Cited by 11
“A large amount of data also suggests that pyroptosis has crosstalk with the tumor immune microenvironment [19].”
BackgroundHornsteiner, F., Vierthaler, J., Strandt, H., Resag, A., Fu, Z., Außerhofer, M., Tripp, C. H., Dieckmann, S. M., Kanduth, M., Farrand, K. J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008606 · Cited by 11
“33 Previous reports suggested that tumor-targeted therapy induces caspase-3 activation 34 which can subsequently lead to pyroptosis initiated by caspase- 3-mediated gasdermin E (GSDME) cleavage in response to various apoptotic stimuli.”
BackgroundMethodInfluentialOkanin Inhibits Cell Growth and Induces Apoptosis and Pyroptosis in Oral Cancer
Chia, W., Chen, K.-Y., Yang, C., Hsieh, C.-C., Tsao, C., Lin, C., Peng, B., Ho, S.-L., Chen, Y., Chang, S.-C., et al. (2024) · Cancers · doi:10.3390/cancers16183195 · Cited by 11
“Many clinically used chemotherapeutics, such as paclitaxel [20], doxorubicin [21,22], cisplatin [21], BRAF inhibitors, MEK inhibitors [22], and sorafenib [23], have been reported to induce pyroptosis in tumor cells as part of their antitumor mechanisms.”
BackgroundDu, F., Han, L., Li, Y., Liu, Y., Li, X., Dang, N., Chu, Q., Yan, J., Fang, Z., Wu, H., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.761134 · Cited by 12
“new evidence that BRAFi induces the occurrence of anti-tumor cell scorching immune responses, which may be a new strategy for the treatment of melanoma (Erkes et al., 2020).”
BackgroundHom, L. M., Sun, S., Campbell, J., Liu, P., Culbert, S., Murphy, I. M., & Schafer, Z. T. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104922 · Cited by 11
Su, L., Wang, D., Purwin, T. J., Ran, S., Yang, Q., Zhang, Q., & Cai, W. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2025.03.021 · Cited by 10
Self-citationImataka, G., Kuwashima, S., Hayashi, S., Ogino, K., Hoshiyama, E., Naruse, K., & Shiraishi, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145071 · Cited by 10
Hu, J., Tian, C., Zhao, Y., Guo, Y., & Chen, S. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02697-w · Cited by 10
“Relations of pyroptosis to the tumor microenvironment (TME) have been established in many studies [8].”
BackgroundZhang, H., Yu, X., Yang, J., He, G., Zhang, X., Wu, X., Li, S., Zhou, Y., Cheng, X., Liu, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933779 · Cited by 10
Zhou, B., Sha, S., Tao, J., Li, J., Shen, C., Zhu, J., Tan, L., Dong, L., & Huang, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-24879-y · Cited by 10
Chen, J., Jiang, R., Guan, W., Cao, Q., Tian, Y., Dong, K., Pan, X., & Cui, X. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.88301 · Cited by 10
“In view of the previous finding that pyroptosis has a far-reaching impact on the immune microenvironment (38,39), we wonder whether pyroptosis is closely related to immunotherapeutic targets such as PD1 and CTLA4, which will be further explored in our ongoing study through bioinformatics analysis…”
BackgroundGuerra, F., Ponziani, F. R., Cardone, F., Bucci, C., Marzetti, E., & Picca, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094783 · Cited by 10
Li, Y., Cui, Q., Guo, R., Ma, Z., Wang, Y., & Xu, X. (2024) · American Journal of Cancer Research · doi:10.62347/rgjo6884 · Cited by 10
“Am J Cancer Res 2024;14(5):2507-2522 Emerging evidence indicates crosstalk between pyroptosis and TME [13, 14], which is known to affect tumor development and progression.”
BackgroundWang, S., Xuan, Z., Chen, Z., Xu, P., Fang, L., Zheng, L., Zhang, Y., Liu, H., Wang, L., Zhang, D., et al. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.97464 · Cited by 10
“Recent studies have shown that chemotherapy, bacterial or viral infections can lead to a novel form of programmed cell death called pyroptosis [25-27].”
Luo, Y., Li, J., Fu, Q., Zhang, P., Song, X., Liu, M., Mo, R., Fu, J., Tang, S., Wu, J., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-96438-0 · Cited by 10
“Targeting BRAF and MEK induces GSDME-mediated pyroptosis in BRAFV600E melanoma cells, resulting in the release of HMGB1 and IL-18, which activate anti-tumour immune responses and promote tumour regression in BRAF mutant melanoma 43 .”
Yin, J., Che, G., Wang, W., Chen, S., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.861284 · Cited by 10
“T cell-mediated anti-tumor immunity (13).”
Zhao, Y., Song, Q., Xu, F., Zhou, Y., Zuo, X., & Zhang, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.823443 · Cited by 10
“For example, BRAF and MEK inhibitors can regulate the tumor immune microenvironment (TIM) through the pyroptosis process (Erkes et al., 2020).”
BackgroundHsu, S., Chen, Y.-E., Shu, E.-D., Ko, C., Chang, W., Lin, I., Li, C., Gallego, R. P., & Chiu, C. (2023) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-023-00678-9 · Cited by 10
“As mentioned previously, pyroptosis-elicited cytokine release can systemically affect the biological functions of immune or stromal cells, further modulating tumor progression (Coffelt et al. 2015; Erkes et al. 2020; Zhang et al. 2018; Zhivaki et al. 2020).”
BackgroundHMGB1: A Central Node in Cancer Therapy Resistance
Alhasan, B. A., Margulis, B. A., & Guzhova, I. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412010 · Cited by 9
“In BRAF-mutant melanoma, combinatorial targeted therapy induces GSDME-mediated pyroptosis with HMGB1 release, creating an immune-stimulatory microenvironment characterized by enhanced T cell and activated dendritic cell infiltration [189].”
Pyroptosis: Turning Up the Heat on Cancer
Zhang, Z., & Lieberman, J. (2026) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041848 · Cited by 10
Deng, X., Wang, Z., Luo, Y., Li, Z., & Chen, L. (2022) · Medicine · doi:10.1097/md.0000000000030304 · Cited by 9
“[45] In particular, the tumor suppressive effect of GSDME, a well-known non-canonical inflammasome member, was observed in immune-deficient mice that lack a pyroptosis-dependent antitumor immune response.[46,47] Moreover, GSDME expression was found to increase antitumor immunity by enhancing the function and abundance…”
BackgroundResultChen, Y., Zhu, F., Che, X., Li, Y., Li, N., Jiang, Z., & Li, X. (2023) · Cell Division · doi:10.1186/s13008-023-00102-w · Cited by 9
“Additionally, poly ADP-ribose polymerase (PARP) has been widely studied as an apoptotic effector protein, but it also reportedly mediates the degradation of DNA and participates in the regulation of pyroptosis [24, 25].”
BackgroundSun, C., Zhan, J., Li, Y., Zhou, C., Huang, S., Zhu, X., & Huang, K. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18348 · Cited by 9
“194 More commonly, the combination of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) has been approved by the FDA for the treatment of melanoma achieving favourable results.”
Background
Metadata
- Authors
- Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., & Aplin, A. E.
- Affiliations
- Thomas Jefferson University (US)
- Corresponding author
- Alnemri, Emad S.
- Aplin, Andrew E.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-02-01
- Volume
- 10
- Issue
- 2
- Pages
- 254-269
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7007378
- OpenAlex
- W2993434511
- Cited by
- 459
- References
- 67
- Citations by year
- 2026: 38 · 2025: 52 · 2024: 78 · 2023: 84 · 2022: 114 · 2021: 72 · 2020: 21
- FWCI
- 18.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- HHS | NIH | National Cancer Institute (CA196278, CA160495, CA182635, CA207855)
- Dr. Ralph and Marian Falk Medical Research Trust (N/A)
- HHS | National Institutes of Health (AR055398, AR074564)
- U.S. Department of Defense (PC150650)
- American Cancer Society (PF-18-096-01-LIB)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- BRAF inhibitors, MEK inhibitors, pyroptosis, gasdermin E, HMGB1, tumor immune microenvironment, antitumor immunity, T cell infiltration, dendritic cells, drug resistance, salvage therapy, targeted therapy
- MeSH terms
- Pyroptosis, Proof of Concept Study, Immune Checkpoint Inhibitors, Animals, Antineoplastic Combined Chemotherapy Protocols, Dendritic Cells, Disease Models, Animal, Female, Humans, Male, Melanoma, Mutation, Skin Neoplasms, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.